Nanocarrier strategies to overcome P-glycoprotein-mediated drug resistance in cancer therapy

• Andreina Quevedo-Enríquez,
• Katty Yi Zhang,
• Denisse Yajaira Enriquez,
• Byron Raul Inapanta,
• Roxana Noemí Peroni and
• Christian Rafael Quijia

Beilstein J. Nanotechnol. 2026, 17, 882–921, doi:10.3762/bjnano.17.64

• diagnosed annually. Among the most prevalent and clinically challenging malignancies are breast, colorectal, gastric, prostate, and lung cancers, particularly non-small cell lung cancer (NSCLC). Despite advances in early detection and treatment, the long-term effectiveness of chemotherapy is frequently

Nanotechnology – a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer

• Filip Gorachinov,
• Fatima Mraiche,
• Diala Alhaj Moustafa,
• Ola Hishari,
• Yomna Ismail,
• Jensa Joseph,
• Maja Simonoska Crcarevska,
• Marija Glavas Dodov,
• Nikola Geskovski and
• Katerina Goracinova

Beilstein J. Nanotechnol. 2023, 14, 240–261, doi:10.3762/bjnano.14.23

• intracellular internalization, and bring advantages over conventional nanocarriers. Keywords: co-delivery nanoparticles; combinatorial therapy; EGFR TKI resistance; non-small cell lung cancer (NSCLC); overcoming and preventing resistance; Introduction Among the malignant diseases, lung cancer takes the lead

• recorded worldwide for both genders, representing 18% of all cancer deaths [4]. There are two main classes of lung cancer based on histological appearance, namely small-cell lung cancer (SCLC), which is highly aggressive, and non-small cell lung cancer (NSCLC), which is more prevalent (85% of all diagnosed

• impact on the discovery of novel therapies based on specific histological types and molecular signatures of cancer. Molecularly targeted therapies that have been developed for a subgroup of non-small cell lung cancer (NSCLC) with endothelial growth factor receptor (EGFR) activating mutations firmly